Abstract
Sorafenib is a tyrosine kinase inhibitor that has been demonstrated to improve the overall survival time of patients with advanced hepatocellular carcinoma (HCC). Although there have been a number of reports of patients achieving complete remission (CR) following sorafenib therapy, the long-term clinical outcomes of these patients have yet to be ascertained. A 72-year-old male patient with chronic hepatitis C, diabetes, hypertension and an old cerebral infarction was referred for the evaluation of a liver mass identified on an abdominal ultrasound. Abdominal computed tomography (CT) demonstrated a 13-cm mass replacing the right lobe of the liver, with portal vein thrombosis. HCC was confirmed by a percutaneous needle biopsy and treated with sorafenib. At 4 months, a follow-up CT demonstrated no enhancing viable lesions in the tumor and recanalization of the portal vein. Sorafenib therapy was continued for 48 months until the patient experienced dyspnea due to congestive heart failure, with pleural effusion. Following the discontinuation of sorafenib, the patient's symptoms improved. The patient followed up without recurrence for 52 months. Subsequent to achieving CR through treatment with sorafenib, long-term sorafenib therapy ...Continue Reading
References
Mar 1, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jordi Bruix, Josep M Llovet
Dec 12, 2003·Lancet·Josep M LlovetJordi Bruix
Oct 7, 2004·Cancer Research·Scott M WilhelmPamela A Trail
Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Oct 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Manuela SchmidingerHerwig Schmidinger
Oct 15, 2008·Molecular Cancer Therapeutics·Scott M WilhelmMark Lynch
Dec 20, 2008·The Lancet Oncology·Ann-Lii ChengZhongzhen Guan
Jul 27, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Thomas E HutsonUNKNOWN Sorafenib TARGET Clinical Trial Group
Jul 6, 2011·Clinical Lung Cancer·Alex A AdjeiDavid Heigener
Sep 3, 2011·The Oncologist·Thomas YauRonnie T P Poon
Mar 20, 2012·Journal of Hepatology·UNKNOWN European Association For The Study Of The Liver, UNKNOWN European Organisation For Research And Treatment Of Cancer
Jan 12, 2013·Digestive Diseases and Sciences·Sun Young AhnSoo Young Park
Apr 5, 2013·World Journal of Gastrointestinal Oncology·Min Su KimMyoung Hun Chae
Apr 11, 2014·Circulation Research·Jason M DuranSteven R Houser
Nov 12, 2014·Future Oncology·Omar Abdel-Rahman, Mona Fouad
Feb 5, 2015·European Journal of Medical Research·Daizhong LiuXielin Feng
Nov 4, 2015·Clinical and Molecular Hepatology·Jung Gil Park